Amarin Corporation Plc ( (AMRN) ) has released its Q1 earnings. Here is a breakdown of the information Amarin Corporation Plc presented to its investors.
Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Amarin Corporation Plc is a pharmaceutical company specializing in cardiovascular disease management, with a focus on its flagship product, VASCEPA®/VAZKEPA®, which is used to reduce cardiovascular risk. The company operates in the healthcare sector and has a global presence with offices and commercial partners worldwide.
In the first quarter of 2025, Amarin Corporation reported financial results that reflect its strategic focus on maximizing the global value of VASCEPA/VAZKEPA. The company emphasized its efforts to maintain a strong balance sheet and capitalize on opportunities in Europe, the U.S., and other global markets.
Key financial highlights for the quarter include a total net revenue of $42.0 million, a decrease of 26% compared to the same period in 2024, primarily due to competition from generic versions in the U.S. Despite this, the U.S. market remains profitable. In Europe, revenue increased significantly, driven by demand in Spain, the UK, and Central Eastern Europe, with further market access achieved in Italy and Austria. The Rest of World markets showed sequential growth, with notable progress in China and Australia.
Amarin’s management remains focused on strategic execution to enhance revenue streams and drive shareholder value. The company regained compliance with Nasdaq listing standards following a 1-for-20 ADS ratio change, ensuring continued access to equity capital markets.
Looking ahead, Amarin aims to expand the impact of VASCEPA/VAZKEPA globally, with a clear focus on efficient revenue generation and cost management to support its financial health. The company is committed to addressing cardiovascular risk worldwide, leveraging its strategic initiatives and partnerships.